Artiva Biotherapeutics is a clinical-stage NK cell therapy company that, in the twelve months leading into mid-2026, executed a strategic pivot from B-cell non-Hodgkin lymphoma into B-cell driven autoimmune disease, secured FDA Fast Track Designation for its lead candidate AlloNK in refractory rheumatoid arthritis, and then raised $300 million in a public offering in May 2026 to fund the next phase of clinical work. The Q2 2026 results reported on August 6, 2026, show a company that is, for the moment, fully funded but operationally accelerating. Net loss for the second quarter was $25.0 million against $21.3 million in the year-ago quarter, with research and development expense of $21.9 million up 22.8% year-over-year, reflecting the cost of running the global Phase 2a basket trial in rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis. Total operating expenses for the first half of 2026 reached $51.3 million, putting the company on a roughly $100 million annualized burn that, against $301.5 million of cash and investments at June 30, 2026, supports a stated runway into the second quarter of 2027 before the May raise.
The single most important event of the period is the May 2026 follow-on offering. The company issued 23.87 million shares of common stock at $11.52 per share and 2.17 million pre-funded warrants at $11.5199 per warrant, generating $300.0 million in gross proceeds and $282.7 million in net proceeds after $17.3 million of issuance costs. Combined with the residual $27.2 million of cash on the balance sheet at the start of the year, this single transaction moved Artiva from a going-concern-adjacent position into a fully funded clinical-stage posture. The share count expanded from 24.6 million shares outstanding at December 31, 2025 to 48.8 million shares outstanding at June 30, 2026, a doubling that mechanically compresses the per-share value of any future clinical win and means the equity is, in effect, the wagging tail of the underlying clinical story rather than its own separate narrative.
The data arc the market is now pricing is the AlloNK autoimmune readout. The company announced in November 2025 that 32 patients with autoimmune disease had been treated with AlloNK and a B-cell targeted monoclonal antibody across company-sponsored and investigator-initiated trials, and the company guided to clinical response data in more than 15 refractory RA patients in the first half of 2026, with planned FDA interactions on pivotal trial design in the same window. Whether the readout confirms the deep B-cell depletion hypothesis at clinical-response magnitudes sufficient to support a pivotal program is the swing variable for the equity. The cash cushion means the company does not have to cut programs if the data disappoint in any single readout, but a soft Phase 2a dataset would meaningfully compress the time value of the option embedded in the current share price.